MAP
Moody Aldrich Partners Portfolio holdings
AUM
$517M
1-Year Return
38.15%
This Quarter Return
+1.45%
1 Year Return
+38.15%
3 Year Return
+181.18%
5 Year Return
+335.56%
10 Year Return
–
AUM
$528M
AUM Growth
+$13M
(+2.5%)
Cap. Flow
+$27M
Cap. Flow
% of AUM
5.12%
Top 10 Holdings %
Top 10 Hldgs %
19.23%
Holding
222
New
70
Increased
61
Reduced
51
Closed
30
Top Buys
| 1 |
Permian Resources
PR
|
$9.47M |
| 2 |
SharkNinja
SN
|
$6.17M |
| 3 |
Vaxcyte
PCVX
|
$5.89M |
| 4 |
ArcBest
ARCB
|
$5.84M |
| 5 |
SL Green Realty
SLG
|
$5.01M |
Top Sells
| 1 |
Green Plains
GPRE
|
$6.34M |
| 2 |
CONMED
CNMD
|
$5.27M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$5.25M |
| 4 |
BWX Technologies
BWXT
|
$5.04M |
| 5 |
Terex
TEX
|
$3.95M |
Sector Composition
| 1 | Healthcare | 16.44% |
| 2 | Industrials | 15.03% |
| 3 | Financials | 14.57% |
| 4 | Technology | 13.45% |
| 5 | Energy | 10.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
UnitedHealth
UNH
$281B
| $581K | 0.11% |
+1,138
| New | +$581K |
|
127
Neurocrine Biosciences
NBIX
$13.7B
| $547K | 0.1% |
+4,863
| New | +$547K |
|
128
BioMarin Pharmaceuticals
BMRN
$10.9B
| $501K | 0.09% |
+5,657
| New | +$501K |
|
129
Steris
STE
$23.9B
| $487K | 0.09% |
2,220
+60
| +3% | +$13.2K |
|
130
Stryker
SYK
$152B
| $483K | 0.09% |
+1,775
| New | +$483K |
|
131
United Therapeutics
UTHR
$17.1B
| $457K | 0.09% |
+2,024
| New | +$457K |
|
132
Diamondback Energy
FANG
$41.6B
| $454K | 0.09% |
+2,932
| New | +$454K |
|
133
Gilead Sciences
GILD
$140B
| $439K | 0.08% |
+5,858
| New | +$439K |
|
134
Incyte
INCY
$16.7B
| $426K | 0.08% |
+7,371
| New | +$426K |
|
135
East-West Bancorp
EWBC
$14.8B
| $425K | 0.08% |
8,072
-179
| -2% | -$9.44K |
|
136
Amazon
AMZN
$2.51T
| $418K | 0.08% |
+3,274
| New | +$418K |
|
137
Boston Scientific
BSX
$160B
| $411K | 0.08% |
+7,801
| New | +$411K |
|
138
Teledyne Technologies
TDY
$25.8B
| $409K | 0.08% |
1,002
-22
| -2% | -$8.99K |
|
139
IQVIA
IQV
$30.9B
| $405K | 0.08% |
+2,049
| New | +$405K |
|
140
Alnylam Pharmaceuticals
ALNY
$59.5B
| $404K | 0.08% |
+2,283
| New | +$404K |
|
141
Celldex Therapeutics
CLDX
$1.5B
| $404K | 0.08% |
+14,687
| New | +$404K |
|
142
Blackstone
BX
$132B
| $388K | 0.07% |
+3,657
| New | +$388K |
|
143
Alphabet (Google) Class A
GOOGL
$2.78T
| $384K | 0.07% |
+2,874
| New | +$384K |
|
144
JPMorgan Chase
JPM
$836B
| $383K | 0.07% |
+2,641
| New | +$383K |
|
145
Stifel
SF
$11.8B
| $380K | 0.07% |
6,178
-137
| -2% | -$8.42K |
|
146
Jones Lang LaSalle
JLL
$14.5B
| $376K | 0.07% |
2,665
+351
| +15% | +$49.6K |
|
|
KRTX
147
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $374K | 0.07% |
2,212
-7,215
| -77% | -$1.22M |
|
148
Exact Sciences
EXAS
$9.98B
| $374K | 0.07% |
+5,481
| New | +$374K |
|
149
Pool Corp
POOL
$11.7B
| $373K | 0.07% |
1,048
-25
| -2% | -$8.9K |
|
150
Broadridge
BR
$29.5B
| $372K | 0.07% |
2,071
+358
| +21% | +$64.2K |
|